

R&D Pipeline

antibody

protein

small molecule

New Molecular Entity

Updated since Dec. 31, 2019

Updated since Jun 30, 2020

Nephrology

As of Sep. 30, 2020

Code Name Generic Name Formulation	Mechanism of Action	Indication	Area	Stage					[In-House or Licensed] Remarks
				Ph I	Ph II	Ph III	Filed	Approved	
KRN321 Darbepoetin Alfa Injection	Long-Acting Erythropoiesis Stimulating Agent	Renal Anemia (on Hemodialysis)	CN						[Kirin-Amgen]
KHK7580 Evocalcet Oral	Calcimimetic	Secondary Hyperparathyroidism	CN KR TW HK						[Mitsubishi Tanabe Pharma]
© RTA 402 Bardoxolone Methyl Oral	Antioxidant Inflammation Modulator	Diabetic Kidney Disease	JP						[Reata]
KW-3357 Antithrombin Gamma Injection	Recombinant Human Antithrombin	Preeclampsia	JP						[In-House]
KHK7791 Tenapanor Oral	NHE3 Inhibitor	Hyperphosphatemia Under Maintenance Dialysis	JP						[Ardelyx]

Oncology

Code Name Generic Name Formulation	Mechanism of Action	Indication	Area	Stage					[In-House or Licensed] Remarks
				Ph I	Ph II	Ph III	Filed	Approved	
KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Mycosis Fungoides and Sézary Syndrome	CH SA AU						[In-House] POTELLIGENT®
© KHK2375 Entinostat Oral	HDAC Inhibitor	Breast Cancer	JP						[Syndax]
KRN125 Pegfilgrastim Injection	Long-Acting Granulocyte Colony- Stimulating Factor	Mobilization of Hematopoietic stem cell into Peripheral blood Automated Injection Device for Decreasing the Incidence of Febrile Neutropenia in Patients Receiving Cancer Chemotherapy	JP JP						[Kirin-Amgen]
© KHK2455 Oral	IDO1 Inhibitor	Solid Tumor Urothelial carcinoma	US US						[In-House] Combination with KW-0761 [In-House] Combination with avelumab
© ME-401 Zandelisib Oral	PI3Kδ Inhibitor	B-cell malignancies Follicular Lymphoma	JP US US EU AU KR others						[MEI Pharma]

※ Since the development of KW-0761 for Adult T-cell Leukemia/Lymphoma was discontinued, the relevant information was deleted from this table.

Immunology/Allergy

Code Name Generic Name Formulation	Mechanism of Action	Indication	Area	Stage					[In-House or Licensed] Remarks
				Ph I	Ph II	Ph III	Filed	Approved	
KHK4827 Brodalumab Injection	Anti-IL-17 Receptor A Fully Human Antibody	Psoriasis Axial Spondyloarthritis (axSpA) Systemic Sclerosis Palmoplantar Pustulosis	MO CN MY JP						[Kirin-Amgen]
© KHK4083 Injection	Anti-OX40 Fully Human Antibody	Atopic Dermatitis	JP US CA EU						[In-House] POTELLIGENT® Human Antibody-Producing Technology
© ASKP1240 Bleselumab Injection	Anti-CD40 Fully Human Antibody	Recurrence of Focal Segmental Glomerulosclerosis (FSGS) in de novo kidney transplant recipients	US						[In-House] Human Antibody-Producing Technology Jointly Developed with Astellas

R&D Pipeline

antibody

protein

small molecule

New Molecular Entity

Updated since Dec. 31, 2019

Updated since Jun 30, 2020

Central Nervous System

As of Sep. 30, 2020

Code Name Generic Name Formulation	Mechanism of Action	Indication	Area	Stage					[In-House or Licensed] Remarks
				Ph I	Ph II	Ph III	Filed	Approved	
KW-6002 Istradefylline Oral	Adenosine A _{2A} Receptor Antagonist	Parkinson's Disease	EU						[In-House]
KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	HTLV-1 associated myelopathy (HAM)	JP						[In-House] POTELLIGENT®
©KW-6356 Oral	Adenosine A _{2A} Receptor Antagonist	Parkinson's Disease	JP						[In-House]
©KHK6640 Injection	Anti-Amyloid Beta Peptide Antibody	Alzheimer's Disease	JP EU						[Immunas Pharma]

Other

Code Name Generic Name Formulation	Mechanism of Action	Indication	Area	Stage					[In-House or Licensed] Remarks
				Ph I	Ph II	Ph III	Filed	Approved	
KRN23 Burosumab Injection	Anti-FGF23 Fully Human Antibody	X-linked Hypophosphatemia (XLH)	TW KW						[In-House] Human Antibody-Producing Technology Jointly Developed with Ultragenyx in US and EU
			QA						
			OM						
			CH HK						
			AU						
			BH						
			CN SA SG						
AMG531 Romiplostim Injection	Thrombopoietin Receptor Agonist	Aplastic Anemia Who Have Had an Inadequate Response to Conventional Therapy	TW						[Kirin-Amgen]
		Idiopathic (Immune) Thrombocytopenic Purpura	KR						
		Aplastic Anemia Who Were Previously Untreated with Immunosuppressive Therapy	CN						
			JP KR TW						
KW-3357 Antithrombin Gamma Injection	Recombinant Human Antithrombin	Disseminated Intravascular Coagulation, Congenital Antithrombin Deficiency	EU						[In-House]